GMAB News and Press, Genmab A/S From 11/02/23

Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with ...

2023-10-23 14:58:57 ET More on Genmab, Seagen, etc. Zai Lab Stock: De-Risking Through Market Tapping Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Seagen/ Astellas succeed in Ph...

TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval an...

2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...

2023-10-18 08:27:42 ET Nuzee ( NUZE ) -33% on proposed public offering of shares . SciSparc ( SPRC ) -16% . Notable Labs (NTBL) -10% . Genmab ( GMAB ) -9% . Maison Solutions ( MSS ) -8% . Aldeyra Therapeutics ( ALDX ...

2023-10-17 07:11:38 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...

Company Announcement Net sales of DARZALEX ® in the third quarter of 2023 totaled USD 2,499 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S ...

2023-09-26 13:00:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and ...

2023-09-25 10:18:09 ET More on AbbVie AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AbbVie: Proving The Bears Wrong Again As Shares Surged AbbVie's Skyrizi outper...

Company Announcement TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy Conditio...